» Articles » PMID: 19468013

Stress Hormone and Circulating Biomarker Profile of Apical Ballooning Syndrome (Takotsubo Cardiomyopathy): Insights into the Clinical Significance of B-type Natriuretic Peptide and Troponin Levels

Overview
Journal Heart
Date 2009 May 27
PMID 19468013
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the stress neurohumoral and cardiac biomarker profile of patients with apical ballooning syndrome (ABS).

Methods: Plasma-free metanephrines, B-type natriuretic peptide (BNP), high sensitivity C-reactive protein (hsCRP) and troponin T, as well as 24-hour urine catecholamines, metanephrines and free cortisol were measured in 19 ABS and 10 ST-elevation myocardial infarction (STEMI) patients.

Results: An antecedent stressful event was identified in 15 ABS patients. There were no differences in plasma normetanephrine (median 0.64 (IQ range 0.43-0.97) nmol/l vs 0.53 (0.32-0.77) nmol/l, p = 0.44), metanephrine (0.10 (0.10-0.22) nmol/l vs 0.16 (0.10-0.38) nmol/l, p = 0.29), or cortisol levels (16.0 (7.3-44.0) microg/dl vs 13.0 (10.5-23.5) microg/dl, p = 0.95) between ABS and STEMI patients. The 24-hour urine metanephrines, catecholamines and cortisol levels were normal in the majority of ABS patients. Troponin T levels were lower (0.62 (0.18-0.84) ng/ml vs 3.80 (2.04-6.57) ng/ml, p<0.001), but BNP levels were higher in ABS compared with STEMI (944 (650-2022) pg/ml vs 206 (140-669) pg/ml, p = 0.009). HsCRP was similarly elevated in the two groups (11.0 (5.1-110.8) mg/l and 24.3 (8.1-88.6) mg/l, p = 0.78).

Conclusions: Catecholamine and cortisol levels were not elevated in our cohort of ABS, suggesting that routine measurement of these stress hormones is unlikely to be of diagnostic value in practice. In contrast to STEMI, ABS is characterised by a greater elevation in BNP and less myonecrosis.

Citing Articles

Reverse Takotsubo cardiomyopathy in the setting of small bowel obstruction: a case report.

Bishev D, Noureldine H, Ortiz F Ann Med Surg (Lond). 2024; 86(9):5557-5560.

PMID: 39239061 PMC: 11374296. DOI: 10.1097/MS9.0000000000002368.


Coronavirus Disease 2019 and Takotsubo Syndrome.

Zhou L, Chen Z, Jiang R, Hu Y, Zhu B, Yang C Rev Cardiovasc Med. 2024; 23(9):298.

PMID: 39077710 PMC: 11262341. DOI: 10.31083/j.rcm2309298.


Impact of Coronary Microvascular Dysfunction in Takotsubo Syndrome: Cause, Consequence or Both?.

Caglioni S, Mele D, Milzi A, Bergamaschi L, Pavon A, Landi A Rev Cardiovasc Med. 2024; 25(5):163.

PMID: 39076465 PMC: 11267194. DOI: 10.31083/j.rcm2505163.


Animal models of Takotsubo syndrome: bridging the gap to the human condition.

Zulfaj E, Nejat A, Haamid A, Elmahdy A, Espinosa A, Redfors B Front Cardiovasc Med. 2024; 11:1351587.

PMID: 38841261 PMC: 11152046. DOI: 10.3389/fcvm.2024.1351587.


Comparison of troponin and natriuretic peptides in Takotsubo syndrome and acute coronary syndrome: a meta-analysis.

Couch L, Garrard J, Henry J, Kotronias R, Alaour B, De Maria G Open Heart. 2024; 11(1).

PMID: 38508657 PMC: 10952941. DOI: 10.1136/openhrt-2024-002607.